Share Price and Basic Stock Data
Last Updated: December 13, 2025, 8:39 am
| PEG Ratio | 1.30 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Par Drugs & Chemicals Ltd operates in the pharmaceuticals sector, a field known for its resilience and significant growth potential. The company reported sales of ₹96 Cr for FY 2023, which remained flat compared to the previous year but showed a gradual increase from ₹75 Cr in FY 2022. This consistent revenue stream suggests a stable demand for its products, despite the pressures of market competition. The trend in quarterly sales also reflects a degree of volatility, with the most recent quarter (September 2023) recording ₹25.89 Cr, which marks a recovery from a dip in June 2023. Interestingly, the sales trajectory over the past few quarters highlights a seasonal pattern, with peaks and troughs indicating varying demand cycles. This can be crucial for investors looking to understand the company’s operational dynamics and market positioning.
Profitability and Efficiency Metrics
Turning to profitability, Par Drugs’ operating profit margin (OPM) stood at 19% for FY 2025, a decrease from 24% in FY 2024, indicating some pressures on cost management. However, the company has maintained a net profit of ₹13 Cr, showcasing its ability to remain profitable even in challenging market conditions. The return on equity (ROE) at 13.6% and return on capital employed (ROCE) at 18.4% suggest that Par Drugs is generating satisfactory returns on its investments. The interest coverage ratio is particularly impressive at 263.72x, highlighting the company’s robust ability to meet its interest obligations. This financial health, combined with a low operational cost structure, places Par Drugs in a strong position relative to many of its peers, although the declining OPM could be a red flag that warrants attention.
Balance Sheet Strength and Financial Ratios
From a balance sheet perspective, Par Drugs appears strong with no borrowings reported, reflecting a debt-free status that many investors find appealing. The company’s reserves have grown to ₹94.13 Cr, signifying not only retained earnings but also a buffer against unforeseen market downturns. The current ratio of 3.31x indicates excellent liquidity, allowing the company to cover its short-term liabilities comfortably. Furthermore, the price-to-book value ratio stands at 1.06x, which suggests that the stock is reasonably valued in relation to its net assets. However, the increasing number of shareholders, which rose to 14,280, could imply that the company is becoming more attractive but may also lead to dilution of control for existing shareholders in the long term.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Par Drugs & Chemicals reveals a significant promoter holding of 73.37%, indicating a strong commitment from the management. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises some concerns about broader market confidence in the stock. The public shareholding is at 26.63%, and the gradual increase in the number of shareholders from 5,676 in December 2022 to 14,280 by September 2025 suggests growing interest among retail investors. This shift may signal a potential for increased liquidity and market participation, which could enhance the stock’s appeal. Yet, the lack of institutional backing may also imply that the stock is not yet considered a safe bet by larger investors, which could affect its price stability in the long run.
Outlook, Risks, and Final Insight
Looking ahead, Par Drugs & Chemicals is poised for both opportunities and challenges. On one hand, the company benefits from a stable operational framework and a solid financial position, with no debt and a healthy liquidity ratio. However, the declining profitability margins and lack of institutional investment are potential risks that could impact future growth. Investors should also consider the competitive landscape of the pharmaceutical industry, where innovation and regulatory changes can swiftly alter market dynamics. The company’s ability to adapt and respond to these changes will be crucial in maintaining its market position. For retail investors, understanding these nuances and keeping an eye on quarterly performance will be essential in making informed investment decisions regarding Par Drugs.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 237/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,250 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,476.95 Cr | 1,156.03 | 52.77 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23.51 | 24.82 | 22.93 | 24.49 | 22.93 | 25.89 | 24.00 | 22.82 | 22.61 | 34.66 | 21.38 | 22.33 | 26.05 |
| Expenses | 19.81 | 18.92 | 19.70 | 19.10 | 18.79 | 18.53 | 18.77 | 16.72 | 18.37 | 23.25 | 19.95 | 19.90 | 22.49 |
| Operating Profit | 3.70 | 5.90 | 3.23 | 5.39 | 4.14 | 7.36 | 5.23 | 6.10 | 4.24 | 11.41 | 1.43 | 2.43 | 3.56 |
| OPM % | 15.74% | 23.77% | 14.09% | 22.01% | 18.05% | 28.43% | 21.79% | 26.73% | 18.75% | 32.92% | 6.69% | 10.88% | 13.67% |
| Other Income | 0.15 | 0.02 | 0.04 | 0.03 | 0.01 | 0.05 | 0.23 | -0.05 | 0.07 | 1.02 | 0.27 | 0.79 | 1.84 |
| Interest | 0.05 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.02 | 0.05 | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 |
| Depreciation | 0.73 | 0.91 | 0.74 | 0.85 | 0.83 | 0.85 | 0.87 | 0.89 | 0.90 | 0.91 | 0.91 | 0.92 | 0.90 |
| Profit before tax | 3.07 | 4.98 | 2.50 | 4.54 | 3.30 | 6.53 | 4.57 | 5.11 | 3.39 | 11.49 | 0.78 | 2.28 | 4.48 |
| Tax % | 25.08% | 25.10% | 25.20% | 24.01% | 25.15% | 25.27% | 25.16% | 27.20% | 25.07% | 25.15% | 24.36% | 27.63% | 25.67% |
| Net Profit | 2.29 | 3.73 | 1.87 | 3.45 | 2.47 | 4.89 | 3.42 | 3.72 | 2.53 | 8.60 | 0.58 | 1.65 | 3.33 |
| EPS in Rs | 1.86 | 3.03 | 1.52 | 2.80 | 2.01 | 3.97 | 2.78 | 3.02 | 2.06 | 6.99 | 0.47 | 1.34 | 2.71 |
Last Updated: August 20, 2025, 5:45 am
Below is a detailed analysis of the quarterly data for Par Drugs & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 26.05 Cr.. The value appears strong and on an upward trend. It has increased from 22.33 Cr. (Mar 2025) to 26.05 Cr., marking an increase of 3.72 Cr..
- For Expenses, as of Jun 2025, the value is 22.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.90 Cr. (Mar 2025) to 22.49 Cr., marking an increase of 2.59 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.56 Cr.. The value appears strong and on an upward trend. It has increased from 2.43 Cr. (Mar 2025) to 3.56 Cr., marking an increase of 1.13 Cr..
- For OPM %, as of Jun 2025, the value is 13.67%. The value appears strong and on an upward trend. It has increased from 10.88% (Mar 2025) to 13.67%, marking an increase of 2.79%.
- For Other Income, as of Jun 2025, the value is 1.84 Cr.. The value appears strong and on an upward trend. It has increased from 0.79 Cr. (Mar 2025) to 1.84 Cr., marking an increase of 1.05 Cr..
- For Interest, as of Jun 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.90 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.92 Cr. (Mar 2025) to 0.90 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.48 Cr.. The value appears strong and on an upward trend. It has increased from 2.28 Cr. (Mar 2025) to 4.48 Cr., marking an increase of 2.20 Cr..
- For Tax %, as of Jun 2025, the value is 25.67%. The value appears to be improving (decreasing) as expected. It has decreased from 27.63% (Mar 2025) to 25.67%, marking a decrease of 1.96%.
- For Net Profit, as of Jun 2025, the value is 3.33 Cr.. The value appears strong and on an upward trend. It has increased from 1.65 Cr. (Mar 2025) to 3.33 Cr., marking an increase of 1.68 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.71. The value appears strong and on an upward trend. It has increased from 1.34 (Mar 2025) to 2.71, marking an increase of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:19 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27 | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 96 | 96 | 101 | 104 |
| Expenses | 20 | 26 | 26 | 40 | 34 | 38 | 46 | 45 | 59 | 78 | 73 | 81 | 86 |
| Operating Profit | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 16 | 16 | 18 | 23 | 20 | 19 |
| OPM % | 27% | 22% | 22% | 17% | 19% | 18% | 17% | 26% | 22% | 19% | 24% | 19% | 18% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 4 |
| Interest | 4 | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 1 | 1 | 1 | 3 | 3 | 3 | 6 | 15 | 13 | 15 | 20 | 18 | 19 |
| Tax % | 40% | 27% | 58% | 42% | 42% | 24% | 21% | 21% | 27% | 25% | 26% | 26% | |
| Net Profit | 1 | 1 | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 11 | 14 | 13 | 14 |
| EPS in Rs | 1.33 | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.78 | 10.86 | 11.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 32% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -100.00% | 0.00% | 50.00% | 66.67% | 140.00% | -25.00% | 22.22% | 27.27% | -7.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | -100.00% | 100.00% | 50.00% | 16.67% | 73.33% | -165.00% | 47.22% | 5.05% | -34.42% |
Par Drugs & Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 10% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 23% |
| 3 Years: | 13% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | -17% |
| 1 Year: | -58% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 12:05 pm
Balance Sheet
Last Updated: December 4, 2025, 1:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 4.48 | 6.15 | 6.15 | 12.30 | 12.30 | 12.30 | 12.30 | 12.30 |
| Reserves | 7.71 | 8.58 | 8.91 | 10.75 | 12.25 | 24.55 | 34.46 | 46.06 | 47.57 | 58.93 | 73.33 | 86.67 | 94.13 |
| Borrowings | 44.12 | 38.46 | 36.49 | 30.55 | 28.87 | 11.58 | 6.01 | 8.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 6.86 | 8.85 | 9.93 | 12.05 | 10.12 | 10.66 | 13.49 | 15.86 | 18.82 | 17.64 | 15.98 | 20.42 | 21.09 |
| Total Liabilities | 61.39 | 58.59 | 58.03 | 56.05 | 53.94 | 51.27 | 60.11 | 76.39 | 78.69 | 88.87 | 101.61 | 119.39 | 127.52 |
| Fixed Assets | 47.06 | 45.11 | 42.61 | 41.53 | 39.04 | 36.34 | 34.40 | 29.91 | 34.10 | 38.45 | 41.31 | 38.91 | 37.70 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | 4.52 | 0.25 | 0.25 | 0.03 | 0.00 | 0.07 |
| Investments | 0.00 | 0.00 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 25.07 | 26.72 |
| Other Assets | 14.33 | 13.48 | 15.36 | 14.46 | 14.84 | 14.87 | 24.91 | 41.95 | 44.33 | 50.16 | 60.26 | 55.41 | 63.03 |
| Total Assets | 61.39 | 58.59 | 58.03 | 56.05 | 53.94 | 51.27 | 60.11 | 76.39 | 78.69 | 88.87 | 101.61 | 119.39 | 127.52 |
Below is a detailed analysis of the balance sheet data for Par Drugs & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 12.30 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.30 Cr..
- For Reserves, as of Sep 2025, the value is 94.13 Cr.. The value appears strong and on an upward trend. It has increased from 86.67 Cr. (Mar 2025) to 94.13 Cr., marking an increase of 7.46 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 21.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.42 Cr. (Mar 2025) to 21.09 Cr., marking an increase of 0.67 Cr..
- For Total Liabilities, as of Sep 2025, the value is 127.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 119.39 Cr. (Mar 2025) to 127.52 Cr., marking an increase of 8.13 Cr..
- For Fixed Assets, as of Sep 2025, the value is 37.70 Cr.. The value appears to be declining and may need further review. It has decreased from 38.91 Cr. (Mar 2025) to 37.70 Cr., marking a decrease of 1.21 Cr..
- For CWIP, as of Sep 2025, the value is 0.07 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.07 Cr., marking an increase of 0.07 Cr..
- For Investments, as of Sep 2025, the value is 26.72 Cr.. The value appears strong and on an upward trend. It has increased from 25.07 Cr. (Mar 2025) to 26.72 Cr., marking an increase of 1.65 Cr..
- For Other Assets, as of Sep 2025, the value is 63.03 Cr.. The value appears strong and on an upward trend. It has increased from 55.41 Cr. (Mar 2025) to 63.03 Cr., marking an increase of 7.62 Cr..
- For Total Assets, as of Sep 2025, the value is 127.52 Cr.. The value appears strong and on an upward trend. It has increased from 119.39 Cr. (Mar 2025) to 127.52 Cr., marking an increase of 8.13 Cr..
Notably, the Reserves (94.13 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -37.12 | -31.46 | -29.49 | -22.55 | -20.87 | -3.58 | 2.99 | 7.68 | 16.00 | 18.00 | 23.00 | 20.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 83 | 81 | 61 | 75 | 67 | 81 | 75 | 90 | 65 | 52 | 60 |
| Inventory Days | 129 | 111 | 158 | 69 | 83 | 81 | 45 | 50 | 60 | 49 | 45 | 58 |
| Days Payable | 171 | 184 | 183 | 135 | 107 | 94 | 96 | 112 | 135 | 73 | 58 | 104 |
| Cash Conversion Cycle | 62 | 10 | 57 | -5 | 51 | 55 | 30 | 13 | 14 | 40 | 40 | 15 |
| Working Capital Days | 102 | 61 | 66 | -46 | -26 | 13 | 39 | 24 | 61 | 50 | 40 | 39 |
| ROCE % | 10% | 9% | 12% | 11% | 12% | 16% | 25% | 22% | 23% | 25% | 18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.86 | 11.78 | 9.21 | 7.49 | 18.87 |
| Diluted EPS (Rs.) | 10.86 | 11.78 | 9.21 | 7.49 | 18.87 |
| Cash EPS (Rs.) | 13.82 | 14.58 | 11.84 | 10.15 | 23.45 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 80.44 | 69.59 | 57.90 | 48.66 | 84.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 80.44 | 69.59 | 57.90 | 48.66 | 84.87 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 1.25 | 0.00 |
| Revenue From Operations / Share (Rs.) | 82.06 | 77.73 | 77.81 | 61.01 | 98.75 |
| PBDIT / Share (Rs.) | 17.60 | 18.74 | 14.99 | 13.36 | 26.34 |
| PBIT / Share (Rs.) | 14.63 | 15.95 | 12.36 | 10.69 | 21.75 |
| PBT / Share (Rs.) | 14.57 | 15.86 | 12.25 | 10.32 | 20.71 |
| Net Profit / Share (Rs.) | 10.86 | 11.79 | 9.21 | 7.49 | 18.87 |
| PBDIT Margin (%) | 21.44 | 24.11 | 19.26 | 21.89 | 26.66 |
| PBIT Margin (%) | 17.83 | 20.51 | 15.88 | 17.52 | 22.02 |
| PBT Margin (%) | 17.75 | 20.40 | 15.74 | 16.92 | 20.97 |
| Net Profit Margin (%) | 13.22 | 15.16 | 11.83 | 12.27 | 19.11 |
| Return on Networth / Equity (%) | 13.49 | 16.93 | 15.91 | 15.38 | 22.23 |
| Return on Capital Employeed (%) | 17.51 | 22.00 | 20.31 | 20.61 | 22.15 |
| Return On Assets (%) | 11.18 | 14.27 | 12.75 | 11.70 | 15.20 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 |
| Asset Turnover Ratio (%) | 0.91 | 1.00 | 1.14 | 0.96 | 0.89 |
| Current Ratio (X) | 3.31 | 4.79 | 3.53 | 2.93 | 2.58 |
| Quick Ratio (X) | 2.94 | 4.46 | 3.15 | 2.61 | 2.39 |
| Inventory Turnover Ratio (X) | 7.66 | 6.97 | 8.13 | 7.68 | 7.47 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 16.69 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 12.31 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 83.31 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 87.69 | 0.00 |
| Interest Coverage Ratio (X) | 263.72 | 215.31 | 138.48 | 36.19 | 25.22 |
| Interest Coverage Ratio (Post Tax) (X) | 163.70 | 136.40 | 86.09 | 21.28 | 15.99 |
| Enterprise Value (Cr.) | 76.93 | 228.45 | 150.02 | 180.36 | 62.64 |
| EV / Net Operating Revenue (X) | 0.76 | 2.39 | 1.57 | 2.40 | 1.03 |
| EV / EBITDA (X) | 3.55 | 9.91 | 8.13 | 10.97 | 3.87 |
| MarketCap / Net Operating Revenue (X) | 1.03 | 2.77 | 1.80 | 2.62 | 1.25 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 83.30 | 0.00 |
| Price / BV (X) | 1.06 | 3.10 | 2.42 | 3.28 | 1.46 |
| Price / Net Operating Revenue (X) | 1.03 | 2.77 | 1.80 | 2.62 | 1.25 |
| EarningsYield | 0.12 | 0.05 | 0.06 | 0.04 | 0.15 |
After reviewing the key financial ratios for Par Drugs & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.82. This value is within the healthy range. It has decreased from 14.58 (Mar 24) to 13.82, marking a decrease of 0.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.06. It has increased from 77.73 (Mar 24) to 82.06, marking an increase of 4.33.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 17.60. This value is within the healthy range. It has decreased from 18.74 (Mar 24) to 17.60, marking a decrease of 1.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.95 (Mar 24) to 14.63, marking a decrease of 1.32.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.57. This value is within the healthy range. It has decreased from 15.86 (Mar 24) to 14.57, marking a decrease of 1.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.79 (Mar 24) to 10.86, marking a decrease of 0.93.
- For PBDIT Margin (%), as of Mar 25, the value is 21.44. This value is within the healthy range. It has decreased from 24.11 (Mar 24) to 21.44, marking a decrease of 2.67.
- For PBIT Margin (%), as of Mar 25, the value is 17.83. This value is within the healthy range. It has decreased from 20.51 (Mar 24) to 17.83, marking a decrease of 2.68.
- For PBT Margin (%), as of Mar 25, the value is 17.75. This value is within the healthy range. It has decreased from 20.40 (Mar 24) to 17.75, marking a decrease of 2.65.
- For Net Profit Margin (%), as of Mar 25, the value is 13.22. This value exceeds the healthy maximum of 10. It has decreased from 15.16 (Mar 24) to 13.22, marking a decrease of 1.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.49. This value is below the healthy minimum of 15. It has decreased from 16.93 (Mar 24) to 13.49, marking a decrease of 3.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 22.00 (Mar 24) to 17.51, marking a decrease of 4.49.
- For Return On Assets (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 14.27 (Mar 24) to 11.18, marking a decrease of 3.09.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.91. It has decreased from 1.00 (Mar 24) to 0.91, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 3.31. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 3.31, marking a decrease of 1.48.
- For Quick Ratio (X), as of Mar 25, the value is 2.94. This value exceeds the healthy maximum of 2. It has decreased from 4.46 (Mar 24) to 2.94, marking a decrease of 1.52.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.66. This value is within the healthy range. It has increased from 6.97 (Mar 24) to 7.66, marking an increase of 0.69.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 263.72. This value is within the healthy range. It has increased from 215.31 (Mar 24) to 263.72, marking an increase of 48.41.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.70. This value is within the healthy range. It has increased from 136.40 (Mar 24) to 163.70, marking an increase of 27.30.
- For Enterprise Value (Cr.), as of Mar 25, the value is 76.93. It has decreased from 228.45 (Mar 24) to 76.93, marking a decrease of 151.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 2.39 (Mar 24) to 0.76, marking a decrease of 1.63.
- For EV / EBITDA (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 5. It has decreased from 9.91 (Mar 24) to 3.55, marking a decrease of 6.36.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 1.06, marking a decrease of 2.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
- For EarningsYield, as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 0.12, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Par Drugs & Chemicals Ltd:
- Net Profit Margin: 13.22%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.51% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.49% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 163.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 11.7 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.22%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 815, Nilamber Triumph, Vadodra Gujarat 390007 | investors@pardrugs.com http://www.pardrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Falgun Vallabhbhai Savani | Chairman & Managing Director |
| Mr. Jignesh Vallabhbhai Savani | Executive Director & CEO |
| Mr. Ghanshayambhai Bhagvanbhai Savani | Whole Time Director |
| Mrs. Nayna Jignesh Savani | Non Executive Director |
| Mr. Pravin Manjibhai Bhayani | Independent Director |
| Mrs. Kajal Chintanbhai Vaghani | Independent Director |
| Mrs. Krishna Mitulbhai Shah | Independent Director |
| Mrs. Bintal Bhaveshkumar Shah | Independent Director |
FAQ
What is the intrinsic value of Par Drugs & Chemicals Ltd?
Par Drugs & Chemicals Ltd's intrinsic value (as of 13 December 2025) is 112.31 which is 22.08% higher the current market price of 92.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 113 Cr. market cap, FY2025-2026 high/low of 226/81.0, reserves of ₹94.13 Cr, and liabilities of 127.52 Cr.
What is the Market Cap of Par Drugs & Chemicals Ltd?
The Market Cap of Par Drugs & Chemicals Ltd is 113 Cr..
What is the current Stock Price of Par Drugs & Chemicals Ltd as on 13 December 2025?
The current stock price of Par Drugs & Chemicals Ltd as on 13 December 2025 is 92.0.
What is the High / Low of Par Drugs & Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Par Drugs & Chemicals Ltd stocks is 226/81.0.
What is the Stock P/E of Par Drugs & Chemicals Ltd?
The Stock P/E of Par Drugs & Chemicals Ltd is 11.7.
What is the Book Value of Par Drugs & Chemicals Ltd?
The Book Value of Par Drugs & Chemicals Ltd is 86.5.
What is the Dividend Yield of Par Drugs & Chemicals Ltd?
The Dividend Yield of Par Drugs & Chemicals Ltd is 0.00 %.
What is the ROCE of Par Drugs & Chemicals Ltd?
The ROCE of Par Drugs & Chemicals Ltd is 18.4 %.
What is the ROE of Par Drugs & Chemicals Ltd?
The ROE of Par Drugs & Chemicals Ltd is 13.6 %.
What is the Face Value of Par Drugs & Chemicals Ltd?
The Face Value of Par Drugs & Chemicals Ltd is 10.0.